UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(AMENDMENT NO. 3)*

Oncocyte Corp
(Name of Issuer)

Common Stock, No. Par Value
(Title of Class of Securities)

68235C107
(CUSIP Number)

December 31, 2022
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)
[ X ] Rule 13d-1(c)
[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 68235C107

13G

Page 2 of 8 Pages

1.
NAMES OF REPORTING PERSONS OR
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Pura Vida Investments, LLC

2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a) [    ]
(b) [ x ]
3.
SEC USE ONLY


4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER

 0

6.
SHARED VOTING POWER

18,056,274*

7.
SOLE DISPOSITIVE POWER

 0

8.
SHARED DISPOSITIVE POWER

18,056,274*

9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

18,056,274*

10.
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) [  ]


11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 15.22%**

12.
TYPE OF REPORTING PERSON (see instructions)

 IA







CUSIP No. 68235C107

13G

Page 3 of 8 Pages

1.
NAMES OF REPORTING PERSONS OR
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Efrem Kamen

2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a) [    ]
(b) [ x ]
3.
SEC USE ONLY


4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 USA


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER

 0

6.
SHARED VOTING POWER

18,056,274*

7.
SOLE DISPOSITIVE POWER

 0

8.
SHARED DISPOSITIVE POWER

 18,056,274*

9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

18,056,274*

10.
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) [  ]


11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

15.22%**

12.
TYPE OF REPORTING PERSON (see instructions)

 IN, HC










CUSIP No. 68235C107

13G

Page 4 of 8 Pages

1.
NAMES OF REPORTING PERSONS OR
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Pura Vida Master Fund, Ltd.

2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a) [    ]
(b) [ x ]
3.
SEC USE ONLY


4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 Cayman Islands


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER

 0

6.
SHARED VOTING POWER

7,427,202

7.
SOLE DISPOSITIVE POWER

 0

8.
SHARED DISPOSITIVE POWER

 7,427,202

9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,427,202

10.
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) [  ]


11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.26%**

12.
TYPE OF REPORTING PERSON (see instructions)

 OO








CUSIP No. 68235C107

13G

Page 5 of 8 Pages


Item 1.

(a)
Name of Issuer

Oncocyte Corp




(b)
Address of Issuers Principal Executive Offices

15 Cushing, Irvine, CA, 92618

Item 2.

(a)
Name of Person Filing

Pura Vida Investments, LLC
Pura Vida Master Fund, Ltd.
Efrem Kamen
(collectively, the "Filers").




(b)
The address of the principal place of the Filers is located at:

Pura Vida Investments, LLC 512 West 22nd Street, 7th Floor, New York, NY 10022




(c)
 For citizenship of Filers, see Item 4 of the cover sheet for each Filer.





(d)
 Title of Class of Securities

Common Stock, No Par Value




(e)
CUSIP Number

68235C107

Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 240.13d-2(b)
 or (c), check whether the person filing is a:


(a)
[  ]
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).





(b)
[  ]
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).





(c)
[  ]
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).



(d)
[  ]
Investment company registered under section 8 of the Investment Company Act of
 1940 (15 U.S.C. 80a-8).



(e)
[x]
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);





(f)
[  ]
An employee benefit plan or endowment fund in accordance with Rule
 13d-1(b)(1)(ii)(F);





(g)
[  ]
A parent holding company or control person in accordance with Rule
 13d-1(b)(1)(ii)(G);











(h)
[  ]
A savings associations as defined in Section 3(b) of the Federal Deposit
 Insurance Act (12 U.S.C. 1813);






(i)
[  ]
A church plan that is excluded from the definition of an investment company
 under section 3(c)(14) of the Investment Company Act of 1940
 (15 U.S.C. 80a-3);





(j)
[  ]
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
CUSIP No. 68235C107

13G

Page 6 of 8 Pages

Item 4. Ownership.

(a) Amount beneficially owned: Pura Vida Investments LLC 18,056,274* shares
 Efrem Kamen 18,056,274* shares Pura Vida Master Fund, Ltd. 7,427,202 shares
(b) Percent of class: Pura Vida Investments LLC 15.22%** Efrem Kamen 15.22%**
 Pura Vida Master Fund, Ltd. 6.26%**
(c) Number of shares as to which the person has: (i) Sole power to vote or to
 direct the vote 0 (ii) Shared power to vote or to direct the vote Pura Vida
 Investments LLC 18,056,274* shares Efrem Kamen Pura Vida Master Fund, Ltd.
 7,427,202 shares (iii) Sole
 power to dispose or to direct the disposition of 0 (iv) Shared power to
dispose
 or to direct the disposition of Pura Vida Investments, LLC 18,056,274* shares
 Efrem Kamen 18,056,274* shares Pura Vida Master Fund, Ltd. 7,427,202 shares

*Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura
 Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund) and certain
 separately managed accounts (the "Managed Accounts," collectively the "Client
 Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment
 manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the
 Managing Member of PVI. Efrem Kamen serves as the managing member of PVI.
 By virtue of these relationships, the Reporting Persons may be deemed to have
 shared voting and dispositive power with respect to the Shares owned directly
 by the Pura Vida Master Fund and the Managed Accounts. This report shall not
 be deemed an admission that the Reporting Persons are beneficial owners of the
 Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as
 amended, or for any other purpose. Each of the Reporting Persons disclaims
 beneficial ownership of the Shares reported herein except to the extent of the
 Reporting Persons pecuniary interest therein
**The percentages herein are calculated based upon 118,643,821 shares of Common
 Stock of the Issuer outstanding per the Issuers Form 10-Q filed with the
 Securities and Exchange Commission on November 3, 2022.

Item 5. Ownership of Five Percent or Less of a Class.

N/A

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the
 Security Being Reported on By the Parent Holding Company.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A



CUSIP No. 68235C107

13G

Page 7 of 8 Pages


Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certification.

          By signing below I certify that, to the best of my knowledge and
 belief, the securities referred to above were not acquired and are not held
 for the purpose of or with the effect of changing or influencing the control
 of the issuer of the securities and were not acquired and are not held in
 connection with or as a participant in any transaction having that purpose or
 effect.

Exhibits.

Exhibit A Joint Filing Agreement.


SIGNATURE


After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and
correct.

Dated: February 14, 2023


Pura Vida Investments, LLC

By: /s/ Efrem Kamen, Managing Member




CUSIP No. 68235C107

13G

Page 8 of 8 Pages

EXHIBIT A
AGREEMENT REGARDING JOINT FILING
OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange
 Commission (the "SEC") any and all statements on Schedule 13D or Schedule
 13G (and any amendments or supplements thereto) required under section 13(d)
 of the Securities Exchange Act of 1934, as amended, in connection with
 purchases and sales by the undersigned of the securities of any issuer
 until such time as the undersigned file with the SEC a statement terminating
 this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.
 For that purpose, the undersigned hereby constitute and appoint Pura Vida
 Investments, LLC, a limited liability company, as their true and lawful
 agent and attorney-in-fact, with full power and authority for and on behalf
 of the undersigned to prepare or cause to be prepared, sign, file with the
 SEC and furnish to any other person all certificates, instruments, agreements
 and documents necessary to comply with section 13(d) and section 16(a) of the
 Securities Exchange Act of 1934, as amended, in connection with said purchases
 and sales, and to do and perform every act necessary and proper to be done
 incident to the exercise of the foregoing power, as fully as the undersigned
 might or could do if personally present, until such time as the undersigned
 file with the SEC a statement terminating this Agreement Regarding Joint
 Filing of Statement on Schedule 13D or 13G.

Dated: February 14, 2023


Pura Vida Investments, LLC

By: /s/ Efrem Kamen, Managing Member

OncoCyte (AMEX:OCX)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024 Plus de graphiques de la Bourse OncoCyte
OncoCyte (AMEX:OCX)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024 Plus de graphiques de la Bourse OncoCyte